MyChesCo on MSN3d
Aclaris Therapeutics Unveils Promising Data on ATI-2138, a Novel Dual ITK/JAK3 InhibitorAclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced significant findings about ATI-2138, a novel investigational drug ...
Within the immune system, interleukin-15 (IL-15) plays a relevant role by boosting the number of cytotoxic T cells and NK cells, the major drivers of anticancer immune response. Researchers from Sotio ...
The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of ...
The use of biologics in psoriasis and psoriatic arthritis management is not linked to the risk of cardiovascular or venous thromboembolic events.
Aclaris Therapeutics (ACRS) announced the availability of a new publication describing properties of Aclaris Therapeutics’ ATI-2138, a novel ...
Data Generated to Date Support Potential for Aclaris’ ATI-2138 to Impact Several Human Inflammatory Diseases - WAYNE, Pa., ...
Analysis by Mount Sinai researcher from First-of-its kind global trial could lead to future therapies to prevent deadly ...
DelveInsight’s, “HDAC Inhibitor Pipeline Insight” report provides comprehensive insights about 40+ companies and 50+ pipeline ...
The Brighterside of News on MSN6d
Revolutionary new cancer treatment destroys tumors in less than 6 daysResearchers from Rice University and Baylor College of Medicine have developed a new treatment that eliminates advanced-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback